ThermoGenesis

ThermoGenesis is a biotechnology company that has developed and commercialized novel cell processing systems and devices for over two decades, serving global researchers, biomanufacturing organizations, and clinicians in the cell and gene therapy field. The company maintains an FDA registered manufacturing facility in Rancho Cordova, CA, and offers products such as the X-LAB® System, BioArchive® System, AXP® II System, and 3D Bag Sets.

ThermoGenesis has over 35 years in the biotechnology industry and currently maintains an FDA registered manufacturing facility at its main office in Rancho Cordova, CA. For more than two decades, ThermoGenesis has developed and commercialized novel cell processing systems and devices.

• X-LAB® System

  A product for cellular processing and storage.

• BioArchive® System

  A product for cellular processing and storage.

• AXP® II System

  A product for cord blood processing.

• 3D Bag Sets

  A product for cellular processing and storage.

• 2022.03.24

  Reported2022.03.28

  ThermoGenesis enters technology license agreement with Boyalife Genomics[6]ThermoGenesis与Boyalife Genomics签订技术许可协议prnewswire.com

  ThermoGenesis entered into a license and technology access agreement with Boyalife Genomics, providing a U.S. license to certain existing and future know-how and intellectual property relating to cell manufacturing and related processes.

• 2021.05.13

  Reported2021.05.13

  ThermoGenesis reports first-quarter 2021 results[7]ThermoGenesis公布2021年第一季度业绩prnewswire.com

  ThermoGenesis Holdings reported financial and operating results for the first quarter ended March 31, 2021, and provided a corporate strategic update.

• 2020.05

  Reported2020.05.14

  ThermoGenesis begins shipping its COVID-19 antibody test kit[8]ThermoGenesis开始发运新冠抗体检测试剂盒prnewswire.com

  ThermoGenesis said it began shipping its SARS-CoV-2 IgM/IgG Antibody Fast Detection Test Kit in May to fill pre-orders and other incoming orders.

• 2020.03.25

  Reported2020.03.25

  ThermoGenesis announces $3.5 million registered direct offering[9]ThermoGenesis 宣布 350 万美元注册直接发行prnewswire.com

  ThermoGenesis Holdings announced definitive agreements with institutional investors for a registered direct offering of 1,000,002 shares at $3.50 per share, with gross proceeds expected to be approximately $3.5 million. The offering closing was expected on or about March 27, 2020, subject to customary conditions.

Read more

1. 1ThermoGenesisthermogenesis.com
2. 2About – ThermoGenesisthermogenesis.com
3. 3Products – ThermoGenesisthermogenesis.com
4. 4CDMO Services – ThermoGenesisthermogenesis.com
5. 5ThermoGenesis (United States)wikidata.org
6. 6ThermoGenesis与Boyalife Genomics签订技术许可协议prnewswire.com
7. 7ThermoGenesis公布2021年第一季度业绩prnewswire.com
8. 8ThermoGenesis开始发运新冠抗体检测试剂盒prnewswire.com
9. 9ThermoGenesis 宣布 350 万美元注册直接发行prnewswire.com